Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
Type:
Grant
Filed:
October 23, 2020
Date of Patent:
March 19, 2024
Assignee:
XENCOR, INC.
Inventors:
Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
Abstract: The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.
Type:
Grant
Filed:
October 9, 2020
Date of Patent:
March 19, 2024
Assignees:
GENENTECH, INC., XENCOR, INC.
Inventors:
John Desjarlais, Matthew Bernett, Michael Hedvat, Rajat Varma, Suzanne Schubbert, Christine Bonzon, Rumana Rashid, Juan Diaz, Patrick Holder, Christine Huang
Abstract: Provided herein are novel antigen binding domains and antibodies (e.g., heterodimeric antibodies) that bind Prostate Specific Membrane Antigen (PSMA). In exemplary embodiments, the anti-PSMA antibodies also bind CD3. Such antibodies that bind PSMA and CD3 are useful, for example in the treatment of PSMA-related cancer.
Type:
Grant
Filed:
May 14, 2021
Date of Patent:
March 5, 2024
Assignee:
Xencor, Inc.
Inventors:
John R. Desjarlais, Alex Nisthal, Michael Hedvat, Matthew Adam Dragovich
Abstract: Provided herein are novel anti-CD28×anti-B7H3 (also referred to as “?CD28×?B7H3”) heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers. Subject ?CD28×?B7H3 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and targeting to B7H3 on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful for enhancing anti-tumor activity when used in combination with other anti-cancer therapies.
Type:
Grant
Filed:
August 19, 2021
Date of Patent:
March 5, 2024
Assignee:
Xencor, Inc.
Inventors:
John R. Desjarlais, Gregory Moore, Michael Hedvat, Juan Diaz, Veronica Gusti Zeng
Abstract: Provided herein are novel GPC3 binding domains, and antibodies that include such GPC3 binding domains (e.g., anti-GPC3×anti-CD3). Also provided herein are methods of using such antibodies for the treatment of GPC3-associated cancers.
Type:
Grant
Filed:
March 10, 2022
Date of Patent:
January 2, 2024
Assignee:
Xencor, Inc.
Inventors:
Alex Nisthal, Nargess Hassanzadeh-Kiabi, Katrina Bykova, Matthew J. Bernett, Rajat Varma
Abstract: The present invention relates to targeted IL-12 heterodimeric Fc fusion proteins, where the fusion proteins bind to human PD-1 or human PD-L1.
Type:
Grant
Filed:
October 2, 2020
Date of Patent:
December 26, 2023
Assignee:
Xencor, Inc.
Inventors:
Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Rumana Rashid, Nargess Hassanzadeh-Kiabi, Michael Hedvat
Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Type:
Grant
Filed:
July 29, 2020
Date of Patent:
November 21, 2023
Assignee:
Xencor, Inc.
Inventors:
Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
Abstract: In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain.
Type:
Grant
Filed:
November 2, 2020
Date of Patent:
November 14, 2023
Assignee:
Xencor, Inc.
Inventors:
Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
Abstract: Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.
Type:
Grant
Filed:
March 9, 2022
Date of Patent:
August 29, 2023
Assignee:
Xencor, Inc.
Inventors:
Matthew S. Faber, Sung-Hyung Lee, Yoon Kyung Kim, Jing Qi, Kendra N. Avery, Seung Y. Chu, Alex Nisthal, Matthew J. Bernett, John R. Desjarlais, Chad Borchert
Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
Type:
Grant
Filed:
June 4, 2021
Date of Patent:
August 8, 2023
Assignee:
Xencor, Inc.
Inventors:
Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
Type:
Application
Filed:
August 11, 2022
Publication date:
July 20, 2023
Applicant:
Xencor, Inc.
Inventors:
Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
Abstract: The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same. The IL-12 Fc fusion proteins are useful for treatment of cancer and can be used in combination with checkpoint blockade.
Type:
Grant
Filed:
August 11, 2022
Date of Patent:
May 23, 2023
Assignee:
Xencor, Inc.
Inventors:
Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Nargess Hassanzadeh-Kiabi, Rumana Rashid
Abstract: The present disclosure is directed to a method of treating neurological disorder comprising peripheral administration to a patient in need thereof a DN-TNF polypeptide that inhibits the activity of soluble TNF- but not transmembrane TNF-?.
Type:
Application
Filed:
June 20, 2022
Publication date:
April 27, 2023
Applicant:
XENCOR, INC.
Inventors:
David Szymkowski, Malu Tansey, Lesley Probert
Abstract: The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.
Type:
Grant
Filed:
December 20, 2019
Date of Patent:
April 4, 2023
Assignee:
Xencor, Inc.
Inventors:
Matthew J. Bernett, John R. Desjarlais, Rajat Varma, Gregory Moore, Juan Diaz, Alex Nisthal, Ke Liu, Rumana Rashid, Eric Chang